Research Article
Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
Table 4
Prolonged QTc interval (corrected QT interval) risk assessment.
| | Prolonged QTc interval | | Characteristic | Patient numbers (%) | Odds ratio (95% CI) | value | Adjusted odds ratio (95% CI) | value |
| | Male | 85 (49.4) | 3.027 (1.389–6.600) | 0.005 | 4.113 (1.772–9.545) | 0.001 | | Baseline ms | 79 (45.9) | 2.136 (1.024–4.456) | 0.043 | 1.681 (0.749–3.774) | 0.208 | | Congestive heart failure | 48 (27.9) | 1.068 (0.481–2.369) | 0.871 | NT | NT | | Hypertension | 53 (30.8) | 0.527 (0.224–1.244) | 0.144 | NT | NT | | Coronary artery disease | 11 (6.3) | 2.134 (0.590–7.719) | 0.248 | NT | NT | | Diabetes mellitus | 60 (34.8) | 0.827 (0.383–1.786) | 0.628 | NT | NT | | Chronic obstructive pulmonary disease | 4 (2.3) | 3.667 (0.499–26.639) | 0.202 | NT | NT | | Chronic kidney disease | 10 (5.8) | 1.555 (0.382–6.327) | 0.537 | NT | NT | | QT prolonging agents | | 1 QT prolonging agent | 29 (16.9) | 1 | | NT | NT | | ≥2 QT prolonging agent | 143 (83.1) | 2.809 (0.801–9.847) | 0.107 | NT | NT | | Tisdale score | | Low risk (<7) | 43 (25) | 1 | | 1 | | | Moderate risk (7–11) | 111 (64.5) | 1.793 (0.679–4.733) | 0.239 | 2.196 (0.764–6.311) | 0.144 | | High risk (≥11) | 17 (9.9) | 4.317 (1.182–15.760) | 0.027 | 6.369 (1.467–27.600) | 0.013 |
|
|
Abbreviation: ms: milliseconds; QTc: corrected QT interval; CI: confidence interval; NT: not tested.
|
